21 August 2018
Visiongain’s new report Global Erythropoietin Market Forecast 2017-2027: Epoetin Alfa, Epoetin Beta, Darbepoetin Alfa, Biosimilars, EPO API Manufacturing indicates that the global erythropoietin market will see $11bn in spending in 2021.
The global erythropoietin market is expected to grow at a CAGR of 7.8% in the first half of the forecast period and CAGR of 4.8% in the second half of the forecast period. The market is estimated at $7.9bn in 2016 and $16.5bn in 2027.
The lead analyst of the report said: “The erythropoietin market is set to experience considerable growth over the next decade. The main drivers for the growth include a growing incidence of renal diseases, increasing prevalence of cancer and higher incidence of chronic and multiple diseases, especially diabetes. Throughout the forecast period, the growth of global EPO drugs market will slow down primarily due to expiry of patents of most common EPO drugs of epoetin-alfa and darbepoetin-alfa, allowing the entry of biosimilars; posing a serious threat to the EPO drugs market. However, the Asia-Pacific region is expected to experience boom period majorly due to improving disposable income and better government medical reimbursement policies.”
The 164-page report contains 84 tables and 93 figures that add visual analysis in order to explain the developing trends within the Global Erythropoietin Market.
Visiongain provides revenue forecasts for the period 2017-2027 as well as qualitative analyses for the leading segments of this market: Epoetin Alfa, Epoetin Beta, Darbepoetin Alfa and Biosimilars. This report also breaks the revenue forecast by application: Anemia (Cancer and HIV Treatment) and Kidney Disorders (ESRD and Dialysis)
The 164-page report offers market forecasts for the US, Canada, Germany, UK, Spain, Italy, France, Japan, China, India, Brazil, Mexico, Saudi Arabia and South Africa. In addition, the report contains a dedicated leading companies chapter covering companies leading the field in the erythropoietin market.
Moreover, this report provides revenue forecast for EPO API Manufacturing, segmented by contract and in-house manufacturing.
The report Global Erythropoietin Market Forecast 2017-2027: Epoetin Alfa, Epoetin Beta, Darbepoetin Alfa, Biosimilars, EPO API Manufacturing report will be of value to anyone who wants to better understand the erythropoietin market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the erythropoietin industry.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
29 July 2021
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
21 July 2021
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
20 July 2021
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.